A new global study reveals that people diagnosed with dementia are living longer than before, thanks to earlier diagnosis and advancements in care that reduce the risk of death post-diagnosis.
A new study led by researchers at Karolinska Institutet has shown that specific blood biomarkers could predict the onset of dementia, including Alzheimer's disease, up to ten years before an actual diagnosis in older adults living independently.
The UK Government has announced its support of new research that will help support those living with dementia, a condition that can severely impact memory, communication, and daily living.
The European Brain Council is a non-profit organization dedicated to promoting brain research and improving the lives of the estimated 179 million Europeans living with brain conditions. Here, they discuss efforts aimed at enhancing care and raising awareness about brain health in Europe.
A new project is expected to help us understand diseases such as cancer and dementia. A major partnership involving Oxford Nanopore Technologies, UK Biobank, NHS England, Genomics England, and the UK government has made this possible.
Dementia is the leading cause of death in the UK, having a huge impact on people living with the condition, their families and the health systems supporting them. We hear from Dementia UK’s Andrew Pike, Head of Policy, Campaigns and Public Affairs, about how the UK Government can help to alleviate these pressures, most notably through aiding specialist nursing support.
Jules Knight, Consultant Admiral Nurse for Young Onset Dementia at Dementia UK, tells us about the prevalence of young onset dementia and some of the challenges that people living with dementia can face.
A second groundbreaking drug for Alzheimer's disease has been rejected for widespread use by the NHS in England; according to the drugs spending watchdog, the drug known as Donanemab does not offer sufficient value for money.
Dhivya Venkat, CEO & Co-Founder of Esya Inc., discusses the urgent need for integrating innovative diagnostics and therapies into the NHS in order to improve dementia care and diagnosis.
According to the World Health Organization (WHO), dementia is the third leading cause of mortality in Europe and the seventh globally, with a societal cost in Europe estimated to be €392bn in 2019. By 2025, 9.1 million people will be living with dementia in the European Union, rising to 14.3 million in 2050. We discuss dementia care provision with Alzheimer Europe.
